1/2022
vol. 18
abstract:
Original paper
Long-term outcomes following drug-eluting balloon or thin-strut drug-eluting stents for treatment of in-stent restenosis stratified by duration of dual antiplatelet therapy (DEB-Dragon Registry)
Natasza Gilis-Malinowska
3
,
Maksymilian Mielczarek
3
,
1.
Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland
2.
Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
3.
First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland
4.
Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
5.
First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
6.
Centre for Heart Disease, University Hospital Wroclaw Department of Heart Disease, Wroclaw Medical University, Poland
7.
Department of Cardiology, 4th Military Hospital, Wroclaw, Poland
8.
Third Department of Cardiology, Medical University of Katowice, Zabrze, Poland
9.
Cardiovascular Institute, Nicolaus Copernicus University, Bydgoszcz, Poland
10.
Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland
11.
Medical University of Warsaw, Warsaw, Poland
12.
AZ Sint Jan Brugge, Belgium
13.
Division of Cardiology, Department of Internal Medicine, Città della Salute e della Scienza, University of Turin, Turin, Italy
14.
Department of Cardiac Surgery, Klinikum Passau, Passau, Germany
15.
Department of Invasive Cardiology, Medical University of Bialystok, Białystok, Poland
16.
Department of Cardiac Surgery, Medical University of Silesia, Katowice, Poland
Adv Interv Cardiol 2022; 18, 1 (67): 14–26
Online publish date: 2022/04/22
Introduction Data regarding the duration of dual antiplatelet therapy (DAPT) in patients with drug-eluting stent restenosis (DES-ISR) treated with percutaneous coronary intervention (PCI) and drug-eluting balloons (DEB) or DES are not unambiguous.
Aim To evaluate the relationship between long-term outcomes and the length of DAPT in patients treated with PCI due to DES-ISR with DEB or DES.
Material and methods Overall, a total of 1,367 consecutive patients with DES-ISR, who underwent PCI with DEB or DES between 2008 and 2019 entered the study. The mean length of the follow-up was 1,298.7 ±794 days. We assessed study endpoints according to the duration of DAPT (≤ 3 vs. > 3 and ≤ 6 vs. > 6 months) before and after propensity score matching (PSM): stroke, target lesion revascularisation (TLR), target vessel revascularisation (TVR), myocardial infarction (MI), death and device oriented composite endpoints (DOCE). Kaplan-Meier estimates were created to differentiate long-term outcomes.
Results Pairwise contrast analysis considering type of PCI (DES vs. DEB) and duration of DAPT (≤ 6 vs. > 6 months) before PSM revealed superiority of DES + DAPT > 6 months vs. DEB + DAPT > 6 months for DOCE (p < 0.001), TVR (p = 0.02) and TLR (p = 0.01). Also, DES+DAPT ≤ 6 months was found to be superior compared to DEB + DAPT ≤ 6 months for DOCE (p < 0.001), TVR (p = 0.02) and TLR (p = 0.01). Kaplan-Meier estimate analysis confirmed that DAPT > 6 months is related to a higher stroke rate (p = 0.01) when compared to ≤ 6 months.
Conclusions Treatment with DAPT in patients with DES-ISR is related to better long-term outcomes in the case of PCI with DES than DEB. DAPT > 6 months is related to the greater rate of strokes, independently of the type of treatment (DES and DEB) than DAPT ≤ 6 months.
keywords:
drug-eluting balloon(s), drug-eluting stent(s), in-stent restenosis, duration of dual antiplatelet therapy, long-term outcomes
|
|